Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis.
The first formulation of a class of products called topical immuno modulators (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the Protopic. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the Elidel. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy.
Abramovits
William
W
Department of Internal Medicine, Dermatology, Baylor University Medical Center in Dallas, Dallas, Texas 75230, USA. research@texasderm.com
Goldstein
Adrian M
AM
Stevenson
Lisa C
LC
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D003880:Dermatology / Q000379:methods / Q000639:trends; D004485:Eczema / Q000188:drug therapy* / Q000276:immunology; D006801:Humans
D000276:Adjuvants, Immunologic